RareDiseasesNews.net

Rare diseases Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Chronic inflammatory demyelinating polyneuropathy: treatment with high dose intravenous Methylprednisolone monthly for five years: 10-year follow up


Although various modalities of treatment of chronic inflammatory demyelinating polyradiculopathy ( CIDP ) there are not any treatment protocol agreed.

Researchers have retrospectively evaluated the 20 CIDP patients ( 14 male, 6 female ). Five patients were excluded from the study because they could not continue their treatments due to various problems during the treatment. The remaining 15 patients treated with monthly high dose intravenous Methylprednisolone for five years ( IVMP ) and followed up for 10 years.

The mean age of the patients was 48.1±14.6 years. The mean duration of disease was 6.8±3.1 years.

Statistically significant difference between the pre-treatment and sixth month modified Rankin scores were found ( p less than 0.001 ).
Similarly, significant improvement was observed at the end of first, fourth and fifth years of treatment.
Statistically significant difference was found between baseline and tenth year modified Rankin scores of 12 patients who were treated with only intravenous Methylprednisolone during 10 years follow-up.

In conclusion, long-term monthly intravenous Methylprednisolone pulse therapy seems to be very effective in the treatment of chronic inflammatory demyelinating polyradiculopathy. ( Xagena )

Börü ÜT et al, Clin Neurol Neurosurg 2014;118: 89-93

XagenaMedicine_2014



Indietro